Synergistic overcoming of cisplatin resistance in ovarian cancer by combined Astragalus Membranaceus and cisplatin treatment: network pharmacology and experimental validation.

ABSTRACT: Ovarian cancer (OC) is a leading cause of mortality among gynecologic malignancies. Cisplatin (DDP) is a first-line chemotherapy agent, but resistance to DDP often develops, compromising its efficacy. Astragalus membranaceus (AS), a traditional Chinese medicine, has shown promise in enhancing chemotherapy sensitivity due to its anti-inflammatory and immunomodulatory properties. This study investigates the potential of AS to overcome DDP resistance in OC. We integrated multiple independent DDP-resistant OC datasets identified 337 DDP resistance-associated targets. Network pharmacology identified 20 active compounds in AS, with 22 potential targets related to DDP resistance. GO and KEGG analyses revealed enrichment in pathways involving inflammation and cell adhesion. Survival analysis indic

SUBMITTER: Wang F 

PROVIDER: S-EPMC12482247 | biostudies-literature | 2025 Sep

REPOSITORIES: biostudies-literature